Trial results for a study investigating previously undiagnosed HIV infection in a hospital setting were posted on 2026-03-30, revealing 6 cases among 300 enrolled participants.
Background
HIV infection remains a significant global health challenge, with a substantial number of individuals unaware of their status. Early diagnosis is crucial for timely treatment initiation, which improves patient outcomes and prevents further transmission. Hospital settings, particularly among patients presenting with HIV indicator conditions (HIV-ICs) or engaging in risky behaviors, represent a key opportunity for identifying undiagnosed cases. Targeted screening in these environments can help bridge the gap in diagnosis and link individuals to care, thereby reducing the burden of advanced disease and public health transmission.
Trial design
This completed cross-sectional study, identified as Phase Not applicable, enrolled 300 participants. The study focused on individuals admitted to the San Raffaele Hospital in Milan for any reason, exhibiting at least one HIV indicator condition and/or engaging in risky behaviors. The conditions studied included Hiv, HIV Infections, and AIDS. The primary objective was to evaluate the prevalence of previously undiagnosed HIV infection in this hospital setting.
Key results
The study reported the following key measurements:
- For the "HIV Diagnostic Test" group, the prevalence of HIV infection was observed in 6 participants out of 300 enrolled.
- Among participants with a "Reactive HIV Test", the median CD4+ Lymphocytes count was 540 cells/microL (Inter-Quartile Range).
- Among participants with a "Reactive HIV Test", the median HIV-RNA level was 1,130,000 copies/mL (Inter-Quartile Range).
What this means
The identification of 6 previously undiagnosed HIV cases among 300 participants in a hospital setting underscores the potential value of targeted screening efforts. These findings suggest that focusing on individuals with HIV indicator conditions or behavioral risk factors during hospital admissions can effectively uncover hidden infections. For those diagnosed, the reported median CD4+ Lymphocytes count of 540 cells/microL and median HIV-RNA level of 1,130,000 copies/mL provide insights into their immune status and viral burden at the time of diagnosis. Early detection through such initiatives allows for prompt linkage to care, initiation of antiretroviral therapy, and prevention of further transmission, ultimately improving individual health outcomes and public health.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06282328, titled "HIV HOspital TEsting: Bringing the Hidden to Light in the Hospital Setting", were posted on 2026-03-30 on clinicaltrials.gov.